NCT05866861View on ClinicalTrials.gov

A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 24, 2023

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2025

Conditions
Systemic Lupus ErythematosusSLE (Systemic Lupus)Autoimmune
Interventions
DRUG

CUG252

CUG252 will be administered by subcutaneous injection.

DRUG

Placebo

Placebo will be administered by subcutaneous injection.

Trial Locations (11)

16635

Site 1003, Duncansville

30046

Site 1007, Lawrenceville

33606

Site 1009, Tampa

33765

Site 1002, Clearwater

36207

Site 1001, Anniston

44106

Site 1010, Columbus

44130

Site 1005, Middleburg Heights

75150

Site 1004, Mesquite

75231

Site 1006, Dallas

92037

Site 1011, La Jolla

98195

Site 1012, Seattle

Sponsors

Lead Sponsor

Cugene Inc.
All Listed Sponsors
lead

Cugene Inc.

INDUSTRY

NCT05866861 - A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter